Schneider, Enja http://orcid.org/0000-0003-1691-917X
Winzer, Riekje http://orcid.org/0000-0001-9780-5857
Rissiek, Anne
Ricklefs, Isabell
Meyer-Schwesinger, Catherine
Ricklefs, Franz L. http://orcid.org/0000-0002-1321-6930
Bauche, Andreas
Behrends, Jochen http://orcid.org/0000-0002-0648-8911
Reimer, Rudolph
Brenna, Santra http://orcid.org/0000-0001-8233-2110
Wasielewski, Hauke http://orcid.org/0000-0003-4819-8231
Lauten, Melchior http://orcid.org/0000-0003-4774-0279
Rissiek, Björn http://orcid.org/0000-0001-5327-5479
Puig, Berta http://orcid.org/0000-0002-2255-8393
Cortesi, Filippo http://orcid.org/0000-0003-0176-067X
Magnus, Tim http://orcid.org/0000-0001-6232-9555
Fliegert, Ralf
Müller, Christa E. http://orcid.org/0000-0002-0013-6624
Gagliani, Nicola http://orcid.org/0000-0001-8514-1395
Tolosa, Eva http://orcid.org/0000-0002-5247-8378
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (RI 2952/1-1, 240245660, RI 2616/3-1, 335447717, FOR2879, 335447717, 335447717, 335447717, TO235/11-1)
Article History
Received: 21 October 2020
Accepted: 17 September 2021
First Online: 8 October 2021
Competing interests
: C.E.M. has given scientific advice to Arcus Biosciences (Arcus Biosciences, Inc. is a publicly-traded biotechnology company working on CD73 inhibitor development). The remaining authors declare no competing interests.